News article

Improvement in lung clearance index and chest CT scores with Elexacaftor/Tezacaftor/Ivacaftor treatment in people with Cystic Fibrosis (pwCF) aged 12 years and older – The RECOVER study. The significant clinical improvements associated with the introduction of ETI therapy for pwCF is now well established, though the impact of ETI on ventilation inhomogeneity and lung structure has remained undescribed. This publication reports data from RECOVER, a real-world s tudy performed in 7 sites in Ireland and the UK.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Source Type: research